Application of Galenic Strategies for Developing Gastro-Resistant Omeprazole Formulation for Pediatrics

dc.contributor.authorRouaz El Hajoui, Khadija
dc.contributor.authorGarcía Montoya, Encarna
dc.contributor.authorSuñé Pou, Marc
dc.contributor.authorSuñé i Negre, Josep M. (Josep Maria)
dc.contributor.authorPérez Lozano, Pilar
dc.date.accessioned2024-10-21T10:12:11Z
dc.date.available2024-10-21T10:12:11Z
dc.date.issued2024-08-01
dc.date.updated2024-10-21T10:12:11Z
dc.description.abstractObjectives: This study addresses a critical need in pediatric pharmacotherapy by focusing on the development of an enteric formulation of omeprazole for pediatric use. Omeprazole, a widely used proton pump inhibitor, is essential for treating various gastrointestinal disorders in children. The main objective is to design a compounding formula that can be prepared in hospital pharmacy services without the need for industrial equipment, which is often unavailable in these settings. Methods: The research applied different galenic strategies to overcome the challenges of omeprazole’s instability in acidic environments and its complex pharmacokinetic and physicochemical properties. The experiments were conducted sequentially, employing salting out, ionic gelation, and matrix granulation strategies. Based on the results obtained, the control conditions and parameters for the various trials were established. Results: Among the techniques used, wet granulation proved to be the most promising, achieving a gastro-resistance level of 44%. In contrast, the ionic gelation and salting-out techniques did not yield satisfactory results. Conclusions: The findings of this study underscore the need to adopt alternative formulation strategies to ensure the stability of omeprazole. This goal requires a multidisciplinary approach and continuous effort to design omeprazole formulations that meet quality standards and appropriate gastro-resistance requirements. Keywords: omeprazole; pediatric pharmaceutical forms; gastro-resistance
dc.format.extent1 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec750932
dc.identifier.issn2227-9067
dc.identifier.urihttps://hdl.handle.net/2445/215917
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/children11080945
dc.relation.ispartofChildren, 2024, vol. 11, num.8
dc.relation.urihttps://doi.org/10.3390/children11080945
dc.rightscc-by (c) Rouaz-El-Hajoui, K. et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationOmeprazol
dc.subject.classificationPediatria
dc.subject.otherOmeprazole
dc.subject.otherPediatrics
dc.titleApplication of Galenic Strategies for Developing Gastro-Resistant Omeprazole Formulation for Pediatrics
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
868245.pdf
Mida:
4.64 MB
Format:
Adobe Portable Document Format